Experimental drug shows promise in refractory DLBCL

An abstract presented at the annual meeting of the American Association for Cancer Research (AACR) regarding patients with aggressive and refractory diffuse large B-cell lymphoma has the attention of those in attendance.

Current treatment modalities can cure as many as 50 percent of patients diagnosed with diffuse large B-cell lymphoma, but the other half are considerably harder to treat, with the most commonly diagnosed subtype (known as activated B-cell or ABC) accounting for as many as 40 percent of all cases. The ABC subtype also has the poorest prognosis.

According to the abstract's lead author, Louis Staudt, MD, PhD, deputy chief of the Metabolism Branch at the National Cancer Institute (NCI), Bethesda, Maryland, a potentially powerful new drug is giving doctors some hope for this subset of patients: Ibrutinib.

Ibrutinib is an oral drug that selectively inhibits Bruton's tyrosine kinase (BTK), an important signaling kinase in the B-cell receptor pathway. It is a first-in-class agent.

Dr. Staudt presented the interim results of patients from a pilot study with ABC DLBCL including one with a CD79BY196C mutation and MYD88 wild type, who had had a complete response to 2 previous cycles of chemotherapy only to relapse. She was then treated with Ibrutinib and 16 months later remains in remission with "no discernible side effects."

A multicenter phase II trial testing ibrutinib against DLBCL has therefore been initiated, said Dr. Staudt.

Source: AACR

More Articles

More Articles

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...

Diffuse large B cell lymphoma prognosis is contingent upon several factors, and can be determined by using a well-...

The term 'metastatic lymphoma' does not refer to a diagnosis. Unlike many of the subtypes of lymphoma we have...

Diagnosing lymphoma is one of the more difficult diagnoses to make in cancer medicine, and contrary to perception, diagnosing lymphoma is not made...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Treatment for Non-Hodgkin’s Lymphomas (NHL) differs from patient to patient. The regimen used depends on the type of...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Follicular lymphoma is classified as a Non-Hodgkin's Lymphoma. It is an indolent (slow-growing) cancer that affects...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

Lymphoma is not difficult to diagnose once a patient and doctor begin to look for signs of cancer. However, Lymphoma–especially...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

The lymphatic system, or lymph system, defends the body from foreign invasion by disease causing agents such as viruses, bacteria, or fungi. The...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...